Article Details
Retrieved on: 2025-01-07 21:53:19
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Despite challenges with Eylea, its top drug, facing competition from Roche's (RHHBY) Vabysmo and a legal battle with Amgen (AMGN) over patent rights, ...
Article found on: www.barchart.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here